Bispecific antibodies
(BY-speh-SIH-fik AN-tee-BAH-dee) A type of antibody that can bind to two different antigens at the same time. Bispecific antibodies are being studied in the imaging and treatment of cancer. They are made in the laboratory.
FDA-Approved Bispecific Antibodies
| Trade Name | Active Ingredient | Year Approved |
|---|---|---|
| Kimmtrak* | tebentafusp-tebn | 2022 |
| Vabysmo | faricimab-svoa | 2022 |
| Tecvayli | teclistamab-cqyv | 2022 |
| Lunsumio | mosunetuzumab-axgb | 2022 |
Currently, bispecific antibody drugs are approved to treat some patients with blood cancers (acute lymphoblastic leukemia, follicular lymphoma, multiple myeloma, large B-cell lymphoma, and diffuse large B-cell lymphoma). Bispecific antibody drugs are also approved to treat: non-small cell lung cancer. cervical cancer.
Bispecific antibodies (BsAbs) recognize two different epitopes. This dual specificity opens up a wide range of applications, including redirecting T cells to tumor cells, blocking two different signaling pathways simultaneously, dual targeting of different disease mediators, and delivering payloads to targeted sites.
Types of Bispecific antibodies
List of Bispecific antibodies
